Tuesday, 15 May 2018

Break
08:00 - 09:30
Foyer

Registration and Welcome Coffee

Plenary Session
09:30 - 10:00
Congress Hall

Welcome Address
CIMT President Christoph Huber
09:30 - 10:00

Plenary Session
10:00 - 11:30
Congress Hall

Cellular Therapy
Chair: Harpreet Singh (Immatics Biotechnologies, Houston, United States)

New modes of T-cell cancer recognition by dissection of immunotherapy successes
Speaker: Andrew Sewell (Cardiff University, Cardiff, United Kingdom)
10:00 - 10:30

ADAPting to solid tumors, advances and challenges for TCR T-cell therapy
Speaker: Gwen Binder-Scholl (Adaptimmune, Philadelphia, United States)
10:30 - 11:00

TIL therapy in melanoma: history of clinical development, current status and plans for the future
Speaker: Rodabe Amaria (University of Texas MD Anderson Cancer Center, Houston, United States)
11:00 - 11:30

Break
11:30 - 13:30
Foyer

Lunch

Corporate Supported Symposium
12:00 - 13:00
Congress Hall

"Immunooncology 2018 and beyond" supported by Bristol-Myers Squibb
Chair: Dirk Jäger (National Center for Tumor Diseases, Heidelberg, Germany)
Immunooncology from mono- to combination therapy - a clinical perspective
Speaker: Viktor Grünwald (Medical School Hannover (MHH), Hanover, Germany)

Resistance to immunotherapy
Speaker: Guy Ungerechts (National Center for Tumor Diseases, Heidelberg, Germany)

Biomarkers in immunooncology - can we predict the outcome of therapy?
Speaker: Andreas Jung (Ludwig-Maximilians-Universität, Munich, Germany)

Plenary Session
13:30 - 15:00
Congress Hall

Counteracting Immune Escape
Chair: Cornelis Melief (ISA Pharmaceuticals, Leiden, Netherlands)
Chair: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)

TNFR family members and cancer immunotherapy: lessons from chronic infection
Speaker: Tania Watts (University of Toronto, Toronto, Canada)

Role of lymphatic vessels in shaping the tumor immune microenvironment
Speaker: Melody Swartz (University of Chicago, Chicago, United States)

Regulation of dendritic cells in tumors
Speaker: Jan P. Böttcher (Technical University Munich, Munich, Germany)

Break
15:00 - 16:00
Foyer

Coffee Break

Poster Session - Therapeutic Vaccination

Reinforcing dendritic cells for cancer immunotherapy: diverse ways and means to target antigens to human skin
Speaker: Lydia Bellmann (Medical University of Innsbruck, Innsbruck, Austria)

A versatile, high-throughput HLA peptidomics pipeline for cancer neoepitope discovery
Speaker: Leon Bichmann (Uni-Tuebingen, Tuebingen, Germany)

Targeted LC-MS detection identifies novel immunogenic HLA-A2-restricted T cell epitopes derived from HPV16 E6 and E7
Speaker: Maria Bonsack (German Cancer Research Center (DKFZ), Heidelberg, Germany)

Predicting observed patient responses to a short-peptide cancer vaccine via clinical trial simulations
Speaker: Liam V Brown (University of Oxford, Oxford, United Kingdom)

The Glioma Actively Personalized Vaccine Consortium (GAPVAC) presents the successful clinical translation of mutated peptide vaccination
Speaker: Valesca Bukur (Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany)
HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients  
Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)

Dendritic cell-targeted nano-vaccines synergize with anti-PD-1/anti-OX40 for melanoma treatment  
Speaker: Joao Conniot (Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal)

Molecular mechanism of immune cell activation by therapeutic melanoma vaccine  
Speaker: Patrycja Czerwińska (Poznań University of Medical Sciences, Poznań, Poland)

A cancer vaccine targeting many neo-antigens is required for efficient eradication of large tumors  
Speaker: Maria De Lucia (University of Naples Federico II, Naples, Italy)

Successful completion of the Mutanome Engineered RNA Immuno-Therapy (MERIT) project  
Speaker: Katrin Frenzel (BioNTech Group, Mainz, Germany)

Bifunctional RNA-nanoparticles to enhance dendritic cell activation and enable MRI-based detection of dendritic cell migration to lymph nodes  
Speaker: Adam Grippin (University of Florida Brain Tumor Immunotherapy Program, Gainesville, United States)

E6/E7 RNA(LIP): An RNA cancer vaccine for treatment of patients with HPV16-positive malignancies  
Speaker: Christian Grunwitz (Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany)

A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors  
Speaker: Maria Hinterberger (Bavarian Nordic, Planegg, Germany)

A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma  
Speaker: Robert A. Jabulowsky (BioNTech AG, Mainz, Germany)

Novel linear doggybone™ DNA vaccine induces anti-tumour immunity via STING and independent of TLR9  
Speaker: Cinderella Jawahar (University of Southampton, Southampton, United Kingdom)

Nucleic Acid based TRL ligand loaded nanocomplexes act as standalone antitumor agents  
Speaker: G. Gokberk Kaya (Bilkent University, Ankara, Turkey)

Discovery and vaccine development for hepatocellular carcinoma - HEPAVAC  
Speaker: Markus W. Löffler (University of Tübingen, Tübingen, Germany)

Retrospective analysis of neoantigen prediction methods  
Speaker: Martin Löwer (TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany)

Modulating T cell immunity in tumors by targeting PD-L1 and neoantigens using a live attenuated oral Salmonella platform  
Speaker: Heinz Lubenau (VAXIMM GmbH, Mannheim, Germany)

Enrichment of gene modified cellular melanoma vaccines with melanoma stem cells or inducible pluripotent stem cells increases immunogenicity and clinical effectiveness in mice  
Speaker: Andrzej Mackiewicz (Poznań University of Medical Sciences, Poznań, Poland)

The immunopeptidomic landscape of breast cancer  
Speaker: Ana Marcu (University of Tuebingen, Tuebingen, Germany)

Multivalent polymeric nanoparticles for combinatorial innovative colorectal cancer immunotherapy and immunomodulation  
Speaker: Ana Isabel Matos (Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal)
Ibrutinib in combination with T-cell based immunotherapy in chronic lymphocytic leukemia (CLL) – mass spectrometry-based HLA ligandome analysis of primary CLL cells approves stable presentation of leukemia-associated antigens
Speaker: Annika Nelde (University of Tübingen, Institute for Cell Biology, Tübingen, Germany)

Nanoparticle-based vaccine improved OX40 anti-tumor efficacy in breast cancer
Speaker: Carina Peres (Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal)

Analysis of the human tumor HLA peptidome based on patient derived xenografts in mice
Speaker: Nataly Rijensky (Technion-Israel Institute of Technology, Haifa, Israel)

Pseudocowpox (PCPV): a viral vector for cancer immunotherapy
Speaker: Karola Rittner (Transgene, Illkirch-Graffenstaden, France)

Local radiotherapy and E7-RNA-LPX vaccination activate non-redundant mechanisms and lead to complete tumor rejection of well-established HPV16+ TC-1 tumors
Speaker: Nadja Salomon (TRON, Mainz, Germany)

Standard therapy supplemented with immunogenic cell death therapy during and subsequent multimodal immunotherapy for GBM
Speaker: Stefaan Van Gool (IOZK, Köln, Germany)

NKG2A blockade potentiates CD8+ T-cell immunity induced by cancer vaccines
Speaker: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)

Biomaterial-based scaffolds improve delivery of therapeutic nanoparticle cancer vaccines to dendritic cells
Speaker: Jorieke Weiden (Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands)

Exosomes co-encapsulating antigen and immunoadjuvants act as an effective therapeutic cancer vaccine
Speaker: Muzaffer Yildirim (Bilkent University, Ankara, Turkey)

Poster Session
15:30 - 18:00
East and West Foyers

Poster Session - Immunomonitoring

Evaluation of immunological changes induced by primary treatment in ovarian cancer patients
Speaker: Thuy Linh Eline Achten (Katholieke Universiteit Leuven, Leuven, Belgium)

Prognostic relevance of immunological changes during first line treatment in epithelial ovarian carcinoma
Speaker: Thaïs Baert (KU Leuven, Leuven, Belgium)

Peripheral blood NKT-cell frequencies and their PD-1 expression levels identify stage IV melanoma patients with poor overall survival under PD-1/CTLA-4 blockade
Speaker: Jonas Bochem (University Medical Center Tübingen, Tübingen, Germany)

T cell Elispot proficiency panel 2017/2018: Evaluating routine T cell Elispot assays
Speaker: Liselotte Brix (Immudex, Copenhagen, Denmark)

MHC class II Dextramers - A new tool for detection of antigen specific CD4+ T-cells
Speaker: Liselotte Brix (Immudex, Copenhagen, Denmark)

High-throughput screening of human tumor-antigen specific CD4 T cells, including neo-antigen reactive cells
Speaker: Carla Costa-Nunes (Translational Tumor Immunology Group, Department of fundamental Oncology, University of Lausanne, Epalinges, Switzerland)

Rapid Target Identification for T-Cell Immune Responses with SpotMixTM Peptide Pools
Speaker: Maren Eckey (JPT Peptide Technologies GmbH, Berlin, Germany)
MemoMAB: Gateway to human antibody repertoires  
Speaker: Christoph Esslinger (Memo Therapeutics AG, Zurich, Switzerland)

CetuGEX and Cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) - p16+ subgroup analysis of the phase 2 RESGEX study  
Speaker: Beate Habel (Glycotope GmbH, Berlin, Germany)

High dimensional analysis of the myeloid cell landscape in human breast cancer metastatic lymph nodes  
Speaker: Rodrigo Nalio Ramos (Institute Curie, Paris, France)

Tumor infiltrating T cells: complete workflows allow faster and improved flow cytometric analysis of syngeneic mouse tumors  
Speaker: Anne Richter (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

New and reproducible method for rapid, standardized PBMC preparation and cyroconservation within the scope of clinical trials  
Speaker: Anne Richter (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Conventional and immune therapies influence the immune microenvironment of malignant brain tumors  
Speaker: Matteo Riva (KU Leuven, Leuven, Belgium)

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival  
Speaker: Saskia J.A.M. Santegoets (Leiden University Medical Center, Leiden, Netherlands)

An improved in vitro assay for monitoring antigen-specific T cell responses using synthetic 20mer peptides  
Speaker: Juliane Schneider (University of Tübingen, Tübingen, Germany)

The spleen functions as a window of a systemic response to detect responders to immune checkpoint inhibitor treatment in murine progressed solid carcinomas by [18F]FDG positron emission tomography (PET)  
Speaker: Barbara F. Schoerg (Eberhard Karls University Tuebingen, Tuebingen, Germany)

Metabolic profiling of secondary lymphatic organs using 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/CT together with eosinophil blood count, S100 and LDH levels is applicable to stratify patients with metastatic melanomas responding to checkpoint inhibitor immunotherapy (CIT)  
Speaker: Johannes Schwenck (Eberhard Karls University Tuebingen, Tübingen, Germany)

Development of an imperacer (Immuno-PCR) assay combining broad assay range and excellent sensitivity to support development of a TNF-receptor agonist antibody drug  
Speaker: Mark Spengler (Chimera Biotec, Bremen, Germany)

Ultra sensitive PK bioanalysis in support of the development of a bi-specific immune-recruiting biotherapeutic  
Speaker: Mark Spengler (Chimera Biotec, Bremen, Germany)

Bioanalytical PK support for Immunotherapeutics: case studies  
Speaker: Mark Spengler (Chimera Biotec, Bremen, Germany)

Finally, empty HLA class I proteins! A disulfide-stabilized variant of HLA-A*02:01  
Speaker: Sebastian Springer (Jacobs University Bremen, Bremen, Germany)

Empty MHC class I molecules: An alternate, convenient, and improved detection tool for antigen specific T cells  
Speaker: Tripti Tamhane (Technical University of Denmark, Lyngby, Denmark)

Immunomonitoring for personalized cancer immunotherapies via ex vivo combinatorial workflow and concurrent high-resolution class I & II ICS  
Speaker: Alexander Ulges (Immatics Biotechnologies GmbH, Tübingen, Germany)

Scalable end-to-end immune repertoire analysis: the ImmunoGenomiX Platform  
Speaker: Henk Jan van den Ham (Enpicom, 's Hertogenbosch, Netherlands)
Tumor epitope detection in monocytes (EDIM) as a marker for antitumoral activity of Newcastle disease virus infusion and modulated electrohyperthermia
Speaker: Stefaan Van Gool (IOZK, Köln, Germany)

Peripheral blood γδ T-cell frequencies correlate with overall survival of stage IV melanoma patients under PD-1 blockade
Speaker: Kilian Wistuba-Hamprecht (University Medical Center Tübingen, Tübingen, Germany)

Disappearance of NY-ESO-1 and Melan-A-specific T-cells from peripheral blood is associated with clinical response in melanoma patients undergoing anti-PD-1 therapy
Speaker: Henning Zelba (University Medical Center Tübingen, Tübingen, Germany)

Poster Session
15:30 - 18:00
East and West Foyers

Poster Session - Tumor Biology and Interaction with the Immune System

Monitoring of T cell infiltration and positioning in colorectal cancer liver metastases using a human tissue-based ex vivo cell migration analysis model
Speaker: Anna Berthel (German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany)

CD47 expression predicts efficacy of macrophage-mediated phagocytosis of tumor cells
Speaker: Kira Böhmer (Crown Bioscience Inc., San Diego, United States)

The oncometabolite R-2-hydroxyglutarate suppresses T cell immunity in IDH1-mutant gliomas
Speaker: Theresa Bunse (German Cancer Research Center, Heidelberg, Germany)

Tumoral MHC class II expression in gliomas
Speaker: Lukas Bunse (German Cancer Research Center (DKFZ), Heidelberg, Germany)

Role of 14F7 monoclonal antibody immunoreactivity against N-glycolyl GM3 ganglioside in colon cancer prognostic
Speaker: Adanays Calvo (National Institute of Oncology and Radiobiology, Havana, Cuba)

Human recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) produced by Lactococcus lactis bacteria acts synergistically with 5-Fluorouracil and Metformin to induce apoptosis in colon cancer cells in vitro
Speaker: Katarzyna Ciaćma (Jagiellonian University Medical College, Kraków, Poland)

Protumoral effects of TLR7 in lung tumors
Speaker: Isabelle Cremer (INSERM UMRS1138, Paris, France)

Durable response to PD-1 blockade in a patient with mismatch repair deficient advanced biliary tract cancer
Speaker: Elena Czink (National Centre for Tumor Diseases, Heidelberg, Germany)

Dominant oncolysis in a syngeneic lung cancer model treated with LCMV-GP – pseudotyped vesicular stomatitis virus
Speaker: Krishna Das (Medical University Innsbruck, Innsbruck, Austria)

A 3D image-based quantification of tumor-immune cell interactions in the presence of immuno-modulators
Speaker: Lidia Daszkiewicz (OcellO, Leiden, Netherlands)

Targeting Stat3 oncogene addiction together with anti PD-1 antibodies as an effective combination for cancer immunotherapy
Speaker: Mara De Martino (IBYME-CONICET, Buenos Aires, Argentina)

Epigenetic modifications upregulate PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoint genes in breast tumor microenvironment
Speaker: Eyad Elkord (Qatar Biomedical Research Institute, Doha, Qatar)
CD200 mimetic PEG-M49 and doxorubicin co-treatment increases CD4CD8 double positive cells in CD200R1 knockout mice and the levels correlate with its anti tumoral effects
Speaker: Nuray Erin (Akdeniz University, Antalya, Turkey)

The effects of TRPV1 agonists on immune response to metastatic breast cancer as well as on tumor growth and metastasis
Speaker: Nuray Erin (Akdeniz University, Antalya, Turkey)

VSV-GP therapy is effective in HNSCC though direct tumor lysis and stimulation of an anti-tumor immune response
Speaker: Patrik Erlmann (ViraTherapeutics, Innsbruck, Austria)

Adipose tissue drives accumulation and activation of mast cells in human cancer specimens
Speaker: Dyke Ferber (National Center for Tumor Diseases (NCT), Heidelberg, Germany)

IL27Ra deficiency alters stromal cell architecture and delays tumor growth in a polyoma middle T oncprotein-driven breast cancer model
Speaker: Annika Fink (Goethe-University Frankfurt, Frankfurt, Germany)

Induction of myeloid-derived suppressor cells via tumor-derived extracellular vesicles in malignant melanoma
Speaker: Viktor Fleming (German Cancer Research Center (DKFZ), Heidelberg, Germany)

The safety, tolerability, and preliminary clinical activity of the CXCR4 inhibitor X4P-001 and nivolumab in renal cell carcinoma patients that are refractory to nivolumab monotherapy
Speaker: Tracy L. Rose (Lineberger Comprehensive Cancer Center, Chapel Hill, United States)

Single-cell transcriptome analysis unveils a heterogeneous and dynamic landscape of tumor infiltrating CDB T cells
Speaker: David Gfeller (University of Lausanne, Epalinges, Switzerland)

c-MET dependent neutrophil responses limit cancer immunotherapy
Speaker: Nicole Glodde (University of Magdeburg, Magdeburg, Germany)

The association between the local immunological microenvironment and the local microbiome in colorectal cancer liver metastases
Speaker: Silke Grauling-Halama (National Center for Tumor Diseases, Heidelberg, Germany)

MDSC and neutrophil recruitment and function in melanoma primary and metastatic lesions
Speaker: Christopher Groth (Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany)

Size matters: The novel immune checkpoint CEACAM1-3S isoform drives NK cell-mediated cytolysis and overall survival in melanoma patients
Speaker: Iris Helfrich (Medical Faculty, University Duisburg-Essen, Essen, Germany)

Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells
Speaker: Dana Hoser (Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany)

Role of tumor-derived extracellular vesicles in immunosuppression in malignant melanoma patients
Speaker: Xiaoying Hu (Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Heidelberg, Germany)

Targeting CD70-positive cancer associated fibroblasts to tackle the immune suppressive tumor microenvironment in colorectal cancer
Speaker: Julie Jacobs (University of Antwerp, Wilrijk, Belgium)

The macrophage immune checkpoint CD47 is a direct target of EMT transcription factors SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT
Speaker: Bassam Janji (Luxembourg Institute of Health, Luxembourg, Luxembourg)
Therapy resistance in renal cell carcinoma correlates with an endothelial cell dependent altered immune cell infiltrate
Speaker: Eva Juengel (Universitätsmedizin Mainz, Mainz, Germany)

B cells and the antibody response in melanoma: mechanisms of immune modulation and translational opportunities
Speaker: Sophia N Karagiannis (King’s College London, London, United Kingdom)

In vivo siRNA knockdown of Wnt1 rescues dendritic cells from β-catenin activation and sensitizes tumors to vaccination
Speaker: Dimitra Kerdidani (BSRC Fleming, Vari, Greece)

Indoleamine 2,3-dioxygenase 1 (IDO1) in human T cells is inducible upon T cell activation and type I interferons
Speaker: Raphael Tobias Kfuri Rubens (Ludwig-Maximilians Universität München, Munich, Germany)

RIG-I-like helicases signaling induced alteration of myeloid-derived suppressor cells phenotype and function unleashes tumor immune control in murine pancreatic cancer
Speaker: Sabrina Viktoria Kirchleitner (Ludwig-Maximilians-Universität München, Munich, Germany)

Cytomegalovirus infection leads to c-MET overexpression, adversely affecting survival and resistance to Temozolomide in glioblastoma
Speaker: Harald Krenzlin (Gutenberg-Universität Mainz, Mainz, Germany)

Investigating the feasibility of tumour infiltrating lymphocyte therapy for paediatric malignancies with high risk and poor prognosis
Speaker: Gray Kueberuwa (University of Manchester, Manchester, United Kingdom)

Omental fat in ovarian cancer induces lymphangiogenesis
Speaker: Benedicte Lenoir (University Heidelberg, Heidelberg, Germany)

Pancreatic tumor-derived factors induce expansion of myeloid cells with high suppressive capacity
Speaker: Philipp Metzger (Klinikum der Universität München, München, Germany)

Investigation of ICOS expression on human and mouse T cell subsets
Speaker: Ramona Murr (Roche Innovation Center Zurich, Schlieren-Zuerich, Switzerland)

Acute myeloid leukemia (AML) promotes generation of iTregs
Speaker: Anya Nikolai (Loyola University Chicago, Maywood, United States)

Urokinase type Plasminogen Activator and Beta-galactoside alpha 2,6 sialyltransferase 1 found in cancer cell exosomes cause autocrine release of CXCR2 ligands
Speaker: Nur Ogan (Akdeniz University, Antalya, Turkey)

Investigation of effects of MSCs on immunoevasive adaptations of breast tumor cell lines, MDA-MB-231 and MCF-7
Speaker: Alper Tunga Özdemir (Ege University, Institute of Health Sciences, Izmir, Turkey)

The effects of mesenchymal stem cell on the macrophage phenotype
Speaker: Bilge Özdemir (Manisa State Hospital, Manisa, Turkey)

Expression of MHC class I determines the prognostic benefit of tumor-infiltrating T cells in ovarian cancer independent of the PD-1/PD-L1 axis
Speaker: Sterre Paijens (University of Groningen, Groningen, Netherlands)

Uncovering miRNAs that affect melanoma cell recognition and killing by antigen specific CD8+ T cells
Speaker: Antonino A. Pane (DKFZ, Heidelberg, Germany)

Manipulation of potassium channels in tumor specific T cells for improved functionality in the suppressive tumor microenvironment
Speaker: Sara Ram Pedersen (Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, Herlev, Denmark)

Evidence for T-cell mediated immunity of HPV vaccination by 3-colour fluorescent EiSpot assay
Speaker: Rosemarie Preyer (GenID GmbH, Straßberg, Germany)
Upregulation of HLA class I expression, CIITA-related block of HLA class II expression and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches  
Speaker: Elise Ramia (University of Insubria, Varese, Italy)

Live-cell assays for immune cell killing of 3D tumour spheroids  
Speaker: Annedore Respa (Essen Bioscience, Welwyn Garden City, United Kingdom)

The Role of RAF-MAPK signalling in Dendritic cells  
Speaker: Kristina Riegel (Mainz University Medical Center/MSU-FZI, Mainz, Germany)

The anatomical location determines type of lymphocyte infiltration in tumors of same etiology  
Speaker: Saskia J.A.M. Santegoets (Leiden University Medical Center, Leiden, Netherlands)

Oncogenic BRAFV600E governs regulatory T cell recruitment during melanoma tumorigenesis  
Speaker: Tamer Basel Shabaneh (Geisel School of Medicine at Dartmouth, Lebanon, United States)

Pan-cancer analysis of human endogenous retrovirus expression reveals markers for prognosis and immunotherapy response in clear cell renal carcinoma  
Speaker: Christof Chiu Smith (UNC - Chapel Hill, Chapel Hill, United States)

Omental fat-induced immune alterations during metastatic spreading of epithelial ovarian cancer: insights from tissue explant culture  
Speaker: Meggy Suarez-Carmona (University Hospital Heidelberg, Heidelberg, Germany)

Characterization of rarely detectable tumor-associated antigens (TAA)-specific CD8+ T cells in HCC patients  
Speaker: Catrin Tauber (University Hospital Freiburg, Freiburg, Germany)

Increased replication and spread of the oncolytic VSV-GP in a syngeneic prostate cancer model does not correlate with improved therapeutic outcome  
Speaker: Carles R. Urbiola (Medical University Innsbruck, Innsbruck, Austria)

Myeloid derived suppressor cells (MDSC) determine outcome in ovarian cancer  
Speaker: Ann Vankerckhoven (KU Leuven, Leuven, Belgium)

Molecular mechanisms responsible for CCR5 regulation on MDSC in melanoma  
Speaker: Rebekka Weber (University Medical Center Mannheim, Mannheim, Germany)

Tumor microenvironment T-cell repertoire and mutational load are independently associated with the outcome of sequential checkpoint inhibition in melanoma  
Speaker: Erik Yusko (Adaptive Biotechnologies, Seattle, United States)

History of prior immunotherapy changes relationship between tumor mutations and TIL repertoire  
Speaker: Erik Yusko (Adaptive Biotechnologies, Seattle, United States)

---

**Plenary Session**
18:00 - 19:00  
**Congress Hall**

**Keynote Lecture**

Chair: Christoph Huber (CIMT, Mainz, Germany)

**Highly multiplex 2D and 3D imaging of the immune system and tumors**  
18:00 - 19:00  
Speaker: Ronald Germain (NIAD, NIH, Bethesda, United States)
Plenary Session
08:00 - 09:30
Congress Hall

Tumor Microenvironment
Chair: Viktor Umansky (German Cancer Research Center DKFZ, Heidelberg, Germany)
Chair: Günter Hämmerling (German Cancer Research Center DKFZ, Heidelberg, Germany)

Potent and durable tumor immunity induced by ADU-S100, a first-in-class STING agonist
Speaker: Andrea van Elsas (Aduro Biotech, Oss, Netherlands)

The Ying and Yang of TAM: Macrophages as effector cells for cytotoxic antibodies in vivo
Speaker: Falk Nimmerjahn (Friedrich-Alexander-University, Erlangen, Germany)

Myelopoiesis and cancer: "Flipping" over monocytes into immune suppressive cells
Speaker: Vincenzo Bronte (University of Verona, Verona, Italy)

Break
09:30 - 10:00
Foyer

Coffee Break

Short Talk Session
10:00 - 11:30
Congress Hall

Short Talk Session I Tumor Biology and Interaction with the Immune System
Chair: Hansjörg Schild (Institute for Immunology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany)
Chair: Steve Pascolo (University Hospital Zurich, Zurich, Switzerland)

Monitoring of T cell infiltration and positioning in colorectal cancer liver metastases using a human tissue-based ex vivo cell migration analysis model
Speaker: Anna Berthel (German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany)

The oncometabolite R-2-hydroxyglutarate suppresses T cell immunity in IDH1-mutant gliomas
Speaker: Theresa Bunse (German Cancer Research Center, Heidelberg, Germany)

Single-cell transcriptome analysis unveils a heterogeneous and dynamic landscape of tumor infiltrating CD8 T cells
Speaker: David Gfeller (University of Lausanne, Epalinges, Switzerland)

In vivo siRNA knockdown of Wnt1 rescues dendritic cells from b-catenin activation and sensitizes tumors to vaccination
Speaker: Dimitra Keridiani (BSRC Fleming, Vri, Greece)

RIG-I-like helicases signaling induced alteration of myeloid-derived suppressor cells phenotype and function unleashes tumor immune control in murine pancreatic cancer
Speaker: Sabrina Viktoria Kirchleitner (Ludwig-Maximilians-Universität München, Munich, Germany)
Tumor microenvironment T-cell repertoire and mutational load are independently associated with the outcome of sequential checkpoint inhibition in melanoma

Speaker: Erik Yusko (Adaptive Biotechnologies, Seattle, United States)

Short Talk Session II Cellular Therapy

Chair: Sébastien Wälchli (Oslo University Hospital, Oslo, Norway)
Chair: Isabel Poschke (German Cancer Research Center DKFZ, Heidelberg, Germany)

10:00 - 10:15
The recognition patterns of T cell receptors identified using peptide-MHC multimers labeled with DNA barcodes
Speaker: Amalie Kai Bentzen (Technical University of Denmark, Lyngby, Denmark)

10:15 - 10:30
In vivo generation of CD4+ and CD8+ CAR-T cells by receptor-targeted lentiviral vectors
Speaker: Julia D. S. Hanauer (Paul-Ehrlich-Institut, Langen, Germany)

10:30 - 10:45
Neoantigen-specific CD8 T cells are structurally and functionally overlapping with CD8 T cells recognizing shared self-tumor and viral epitopes
Speaker: Morgane Magnin (Lausanne University Hospital Centre (CHUV), Epalinges, Switzerland)

10:45 - 11:00
Super-resolution microscopy dSTORM reveals CD19dim expression on a subset of myeloma cells that can be targeted with CD19-CAR T cells
Speaker: Thomas Nerreter (Universitätsklinikum Würzburg, Würzburg, Germany)

11:00 - 11:15
Off-target toxicity risk evaluation for TCR-based therapies guided by immunopeptidomics data of a comprehensive set of more than 650 primary normal tissue samples
Speaker: Heiko Schuster (Immatics Biotechnologies GmbH, Tübingen, Germany)

11:15 - 11:30
Intestinal graft-versus-host disease is driven by BATF-dependent IL-7RhiGM-CSF+ T cells
Speaker: Evelyn Ullrich (Johann Wolfgang Goethe-University, Children's Hospital, Frankfurt, Germany)

Short Talk Session III New Targets & New Leads

Chair: John Castle (Agenus Inc, Lexington, United States)
Chair: Angelika Riemer (German Cancer Research Center DKFZ, Heidelberg, Germany)

10:00 - 10:15
Identification of a naturally presented myeloma-associated BCMA peptide as an immunogenic T-cell epitope for immunotherapeutic approaches
Speaker: Tatjana Bilich (University of Tübingen, Institute for Cell Biology, Tübingen, Germany)

10:15 - 10:30
Immunopeptidomic profiling of triple negative breast cancer identifies potential immunotherapy target antigens
Speaker: Demin Li (University of Oxford, Oxford, United Kingdom)

10:30 - 10:45
KY1055: a novel ICOS/PD-L1 bispecific antibody, enhances T cell activation and delivers potent monotherapy anti-tumour responses in vivo
Speaker: Matthew McCourt (Kymab, Cambridge, United Kingdom)
Glyco-engineering of an anti-CD40 antibody enhances its agonistic activity
Speaker: Phillip Schiele (Glycotope GmbH, Berlin, Germany)

Database matching of de novo sequencing candidates - a new strategy for MHC peptide identification
Speaker: Andreas Schlosser (Universität Würzburg, Würzburg, Germany)

Theranostic tumor imaging of neuroblastoma using radiolabeled αCD276-antibody
Speaker: Dominik Sonanini (Eberhard Karls University of Tübingen, Tübingen, Germany)

Break
11:30 - 14:00
Foyer

Lunch

Plenary Session
12:00 - 13:30
Congress Hall

CAR T-Cell Therapy organized by CARAT
Chair: Christian Buchholz (Paul-Ehrlich-Institut, Langen, Germany)
Chair: Andrew Kaiser (Miltenyi Biotech, Bergisch Gladbach, Germany)

Chimeric antigen receptor T cells: advances in cellular engineering and clinical development
Speaker: Bruce Levine (University of Pennsylvania, Philadelphia, United States)

T-cell engineering for cancer applications
Speaker: Martin Pule (University College London, London, United Kingdom)

Cell therapy between academic research and company driven drug development
Speaker: Peter Borchmann (University Hospital of Cologne, Cologne, Germany)

Combination Therapies
Chair: Sjoerd H. van der Burg (Leiden University Medical Center, Leiden, Netherlands)
Chair: Dirk Jäger (National Center for Tumor Diseases, Heidelberg, Germany)

Stromal activation in cancer immunology and immunotherapy
Speaker: Shannon Turley (Genentech, San Francisco, United States)

Mechanistic insights into the immune adjuvant effect of radiotherapy
Speaker: Sandra Demaria (Weill Cornell Medical College, New York, United States)

The anti-TGFβ neutralizing antibody, SAR439459, blocks immunosuppression and exhibits anti-tumor activity in combination with anti-PD1
Speaker: Jack Pollard (Sanofi Oncology, Cambridge, United States)
Break
15:30 - 16:30
Foyer

Coffee Break

Poster Session
15:30 - 18:30
East and West Foyers

Poster Session - Cellular Therapy

The CliniMACS Prodigy® and CliniMACS® Electroporator platforms enable automated and GMP-compliant production of dendritic cell vaccines
Speaker: Caroline Angerer (Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany)

The recognition patterns of T cell receptors identified using peptide-MHC multimers labeled with DNA barcodes
Speaker: Amalie Kai Bentzen (Technical University of Denmark, Lyngby, Denmark)

LP-141 CliniMACS Prodigy System: primary cross-presenting DCs for the generation of cancer vaccines
Speaker: Eva Bergschneider (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Automated cell processing and electroporation for generation and genetic engineering of monocyte-derived dendritic cells
Speaker: Eva Bergschneider (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Exploring human T lymphocytes redirected to the tumor neoantigen EGFRvIII for adoptive cellular immunotherapy of non-small cell lung cancer
Speaker: Anita Bhatti (University Medical Center Mainz, Mainz, Germany)

The development of human γδ-T antigen presenting cells as a clinical grade cancer vaccine
Speaker: Miroslava Blahova (University of Birmingham Medical School, Birmingham, United Kingdom)

In vitro generation of tumor antigen-specific T cells from patient and healthy donor stem cells
Speaker: Sarah Bonte (Ghent University, Ghent, Belgium)

Automated ex vivo expansion of low numbers of tumor-reactive T cells on the CliniMACS Prodigy®
Speaker: Elvira Criado-Moronati (Miltenyi Biotec, Bergisch Gladbach, Germany)

Nanobody based dual specific CARs
Speaker: Stijn De Munter (Ghent University, Gent, Belgium)

Molecular mechanisms regulating TCR affinity-improved T cells against the NY-ESO-1 tumor antigen
Speaker: Efe Erdes (Lausanne University Hospital Centre (CHUV), Epalinges, Switzerland)

Balancing CD28 costimulation and CD3ζ activation in CD19 CAR T cells enhances therapeutic potency by delaying T cell differentiation and exhaustion
Speaker: Judith Feucht (Memorial Sloan Kettering Cancer Center, New York City, United States)

Selecting CD8-specific DARPins for T lymphocyte-directed gene delivery
Speaker: Annika Melanie Frank (Paul Ehrlich Institute, Langen, Germany)

The effect of anti-CTLA-4 blockade on the expansion of tumor-infiltrating lymphocytes for adoptive cell therapy in metastatic ovarian cancer
Speaker: Christina Friese (Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, Herlev, Denmark)

In vivo generation of CD4+ and CD8+ CAR-T cells by receptor-targeted lentiviral vectors
Speaker: Julia D. S. Hanauer (Paul-Ehrlich-Institut, Langen, Germany)

Intracerebral immunomodulation using genetically engineered mesenchymal stem cells induces long-term survival and immunity in glioblastoma
Speaker: Daniela Hirsch (apceth Biopharma GmbH, Munich, Germany)
Affinity maturation and validation of a COL6A3-002-specific T cell receptor for improving performance in adoptive cell therapy  
Speaker: Meike Hutt (Immatics Biotechnologies GmbH, Tuebingen, Germany)

CD4 T-cell based immunotherapy of cancer  
Speaker: Else Marit Inderberg (Oslo University Hospital- The Norwegian Radium Hospital, Oslo, Norway)

Substantially enhanced CAR-gene transfer rates by CD4- and CD8-targeted lentiviral vectors while retaining selectivity  
Speaker: Arezoo Jamali (Paul Ehrlich Institute, Langen, Germany)

Best chimeric antigen receptor (CAR) expressing vehicle: peripheral versus tumour infiltrating lymphocytes  
Speaker: Milena Kalaisitsidou (University of Manchester, Manchester, United Kingdom)

Adoptive immunotherapy using DNA-demethylated Th-cells as antigen presenting cells induces tumor regression in patients with relapsed glioblastoma  
Speaker: Alexei F. Kirkin (CytoVac A/S, Hørsholm, Denmark)

Substantially enhanced CAR-gene transfer rates by CD4- and CD8-targeted lentiviral vectors while retaining selectivity  
Speaker: Arezoo Jamali (Paul Ehrlich Institute, Langen, Germany)

Selective bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor therapy  
Speaker: Sebastian Kobold (Klinikum der Universität München, München, Germany)

Arming T cells with C-X-C-motive receptor 6 enables adoptive T cell therapy of cancer  
Speaker: Sebastian Kobold (Klinikum der Universität München, München, Germany)

Murine-human hybrid tyrosinase reactive T-cell receptor increases antigen reactivity and cytokine production  
Speaker: Yi Wei Lim (Loyola University Chicago, Chicago, United States)

PD-L1-specific immunocytokines augment functionality and antitumor activity of CAR-engineered NK cells  
Speaker: Aline Lindner (Georg-Speyer-Haus, Frankfurt am Main, Germany)

Development of a chimeric costimulatory receptor to enhance CAR T therapy  
Speaker: Dominik Lock (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Neoantigen-specific CD8 T cells are structurally and functionally overlapping with CD8 T cells recognizing shared self-tumor and viral epitopes  
Speaker: Morgane Magnin (Lausanne University Hospital Centre (CHUV), Epalinges, Switzerland)

“Built-in” PD-1 Blockade: a strategy to counteract inhibition of effector cells for adoptive cell cancer therapy  
Speaker: Nadia Mensali (Oslo University Hospital Radiumhospitalet, Oslo, Norway)

T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression  
Speaker: Özcan Met (University Hospital Herlev, Copenhagen, Herlev, Denmark)

Donor-specific immunomodulation by clinical MIC cell infusion - a phase I study (TOL-1)  
Speaker: Christian Morath (Kidney Center Heidelberg, Heidelberg, Germany)

Development of flow cytometric assays for CAR T cell manufacturing and patient immunomonitoring  
Speaker: Marsilius Mues (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Super-resolution microscopy dSTORM reveals CD19dim expression on a subset of myeloma cells that can be targeted with CD19-CAR T cells  
Speaker: Thomas Nerreter (Universitätsklinikum Würzburg, Würzburg, Germany)

Induction of tolerogenic dendritic cells in vitro by mitomycin C-induced peripheral blood mononuclear cells  
Speaker: Ming Ni (University Clinic Heidelberg, Heidelberg, Germany)

In vitro expanded tumor-infiltrating lymphocytes across various sarcoma subtypes highly express LAG3 and comprise multifunctional T cells with tumor killing capacity  
Speaker: Morten Nielsen (Center for Cancer Immune Therapy, Herlev University Hospital, Herlev, Denmark)
Ex vivo generation and expansion of CAR-engineered NK cells for adoptive cancer immunotherapy
Speaker: Pranav Oberoi (Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany)

CD19 splicing and mutation linked to CART-19 immunotherapy resistance
Speaker: Claudia Paret (Medical University of Mainz, Mainz, Germany)

T Cell Receptor/DAP10 chimera as a means to attaining persistent anti-tumor T cell response
Speaker: Lourdes Plaza-Rojas (Loyola University Chicago, Maywood, United States)

Optimal-affinity T cell receptors targeting NY-ESO via MHC II help MHC I-restricted T cell receptors in tumour regression
Speaker: Lucia Poncette (Max Delbrück Center for Molecular Medicine, Berlin, Germany)

Heterogeneity and dynamics of the tumor-infiltrating lymphocyte repertoire in melanoma and pancreatic cancer patients
Speaker: Isabel Poschke (German Cancer Research Center DKFZ, Heidelberg, Germany)

Immunotherapy of ovarian cancer by targeting Claudin-6 with CAR-engineered T cells
Speaker: Katharina Reinhard (BioNTech Cell & Gene Therapies GmbH, Mainz, Germany)

Update on the clinical trial preparations concerning a MAGE-A1-specific T cell receptor
Speaker: Vivian Scheuplein (Max-Delbrück-Centrum, Berlin, Germany)

Off-target toxicity risk evaluation for TCR-based therapies guided by immunopeptidomics data of a comprehensive set of more than 650 primary normal tissue samples
Speaker: Heiko Schuster (Immatics Biotechnologies GmbH, Tübingen, Germany)

TCR-pMHC 2D affinity and bond lifetime under force correlate with tumor-specific CD8 T cell responsiveness
Speaker: Julien Schmidt (University of Lausanne, Epalinges, Switzerland)

Modifying melanoma immune microenvironment by heterologous prime-boost vaccination with adenovirus and modified vaccinia Ankara virus vectors
Speaker: Naveen Shridhar (University Clinic Magdeburg, Magdeburg, Germany)

How to make a fishing rod for adoptive cellular therapy: the ACTolog® approach, a multi-targeted endogenous T-cell therapy
Speaker: Stefanie Souczek (Immatics Biotechnologies GmbH, Tuebingen, Germany)

PI3Kδ inhibition by idelalisib for optimized generation of CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
Speaker: Sophia Stock (University Hospital Heidelberg, Heidelberg, Germany)

Enhancing cancer immunotherapy using responsive biomaterials
Speaker: Li Tang (École polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland)

Intestinal graft-versus-host disease is driven by BATF-dependent IL-7RhiGM-CSF+ T cells
Speaker: Evelyn Ullrich (Johann Wolfgang Goethe-University, Children’s Hospital, Frankfurt, Germany)

Enhancing the activation and releasing the brakes of NK cells for treatment of Multiple Myeloma
Speaker: Evelyn Ullrich (Johann Wolfgang Goethe-University, Children’s Hospital, Frankfurt, Germany)

Combining conventional therapy with immunotherapy: a risky business?
Speaker: Ann Vankerckhoven (KU Leuven, Leuven, Belgium)

A two chain chimeric antigen receptor (CAR) scaffold recruits T-cell endogenous CD3 subunits for physiological CAR signaling and induces efficient tumor cell killing in vitro and in vivo
Speaker: Matthias Birtel (TRON - Translational Oncology at the University Medical Center Mainz gGmbH, Mainz, Germany)
Speaker: Ralf-Holger Voss (University Medical Center (UMC) of the Johannes Gutenberg University Mainz, Mainz, Germany)
Depletion of macrophages in the tumor-draining lymph node enhances dendritic cell-induced anti-tumor immunity
Speaker: Heleen Vroman (Erasmus MC, Rotterdam, Netherlands)

Trapping TGF-β with decoy receptors restricts TGF-β mediated immune cell suppression
Speaker: Aleksandra Vuchkovska (Loyola University Chicago, Maywood, United States)

Pre-clinical validation of a TCR redirected universal NK cell line
Speaker: Sébastien Wälchli (Oslo University Hospital, Oslo, Norway)

Inhibition of IL-10 secretion in CAR-engineered NK cells modulates polarization of bystander macrophages and enhances dendritic cell maturation
Speaker: Anja Waldmann (Georg-Speyer-Haus, Frankfurt, Germany)

A new cellular immunotherapy for the treatment of multiple myeloma without development of graft-versus-host disease
Speaker: Sofi Yado (Ariel University, Ariel, Israel)

Quantitative live-cell imaging as an efficient tool for the assessment of safety and efficacy of engineered T cells and bispecific molecules
Speaker: Sara Yousef (Immatics biotechnologies GmbH, Tübingen, Germany)

Preclinical characterization of an off-the-shelf chimeric antigen receptor-engineered NK cell therapeutic for adoptive cancer immunotherapy
Speaker: Congcong Zhang (Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany)

Poster Session
15:30 - 18:30
East and West Foyers

Poster Session - Improving Immunity

Mouse models of pancreatic cancer for development of combinatorial immunotherapies involving cytostatic agents and agonist anti-CD40 antibody
Speaker: Daniel Baumann (German Cancer Research Center (DKFZ), Heidelberg, Germany)

Role of the Interleukin-33/ST2L-axis for the CD8-dependent anti-cancer cytotoxicity - Protease- versus receptor-dependent regulation of Interleukin-33 bioactivity
Speaker: Caroline Dreis (Goethe University, pharmazentrum Frankfurt, Frankfurt/Main, Germany)

Targeted immunotherapy with oncolytic measles virus vaccines
Speaker: Christine E. Engeland (National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany)

Fc effector function contributes to the activity of human anti-CTLA-4 antibodies
Speaker: Andrew Furness (Royal Marsden NHS Foundation Trust, London, United Kingdom)

High rate of objective anti-tumor response in 9 patients with primary or recurrent glioblastoma after viro-immunotherapy with oncolytic parvovirus H-1 in combination with bevacicumab and PD-1 checkpoint blockade
Speaker: Karsten Geletneky (Klinikum Darmstadt, Darmstadt, Germany)

Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable treatment of solid tumors with T cell therapies
Speaker: Riikka Havunen (University of Helsinki, Helsinki, Finland)

Intratumoral RNA treatment: a promising approach for the therapy of solid tumors
Speaker: Katja Fiedler (CureVac AG, Tübingen, Germany)

Human interleukin-2 (IL-2)/anti-IL-2 antibody complexes preferentially stimulate effector cells and show strong efficacy in tumor models
Speaker: Andreas Katopodis (Novartis Institutes of Biomedical Research, Basel, Switzerland)

Abrogation of the immunosuppressive tumor microenvironment in cholangiocarcinoma by targeting PD-1 or GITR
Speaker: Jaap Kwekkeboom (Erasmus MC University Medical Center, Rotterdam, Netherlands)
Investigation of combined immune checkpoint blockade in human malignant pleural mesothelioma  
Speaker: Elly Marcq (University of Antwerp, Antwerp, Belgium)

Activin-A protects against lung cancer progression by potentiating anti-tumor immunity  
Speaker: Ioannis Morianos (Biomedical Research Foundation of the Academy of Athens, Athens, Greece)

Rapid generation of peptide-HLA complexes with disulfide-stabilized empty HLA-A*02 molecules for high throughput screening approaches  
Speaker: Andreas Moritz (Immatics biotechnologies, Tübingen, Germany)

Type I IFN responsiveness of melanoma is cell state dependent and can be both harnessed and suppressed to enhance oncolytic virotherapy efficacy  
Speaker: Janne Ruotsalainen (University Hospital Magdeburg, Magdeburg, Germany)

Immunomodulatory properties of the glyco-engineered anti-EGFR antibody Tomuzotuximab  
Speaker: Phillip Schiele (Glycotope GmbH, Berlin, Germany)

dermaject® intradermal injection device ensures superficial and reproducible intradermal injections in human ex vivo skin  
Speaker: Sandra Schulz (Hahn-Schickard, Villingen-Schwenningen, Germany)

Loss of myeloid cell GCN2 drives progression in experimental melanomas during immune checkpoint inhibition  
Speaker: Jana K. Sonner (German Cancer Research Center DFKZ, Heidelberg, Germany)

Dissecting the synergistic effect of chemotherapy and immunotherapy on anti-tumoral T cell functions in breast cancer  
Speaker: Lorenzo Spagnuolo (Oncode Institute, Netherland Cancer Institute, Amsterdam, Netherlands)

An improved preclinical immuno-oncology platform: Patient-derived tumor xenografts in humanized NSG-SGM3 mice  
Speaker: Ralph Gareus (The Jackson Laboratory, Bar Harbor, United States)

---

**Poster Session**

15:30 - 18:30  
East and West Foyers

**Poster Session - New Targets & New Leads**

The AA protein-based model explains how cancer could arise  
Speaker: Adouda Adjiri (Setif-1 University, Setif, Algeria)

Peptide-based immune system engagers targeting α3 integrin prevent tumor growth and metastasis in a syngeneic triple-negative 4T1 tumor model  
Speaker: Mona Ali Mahmoud Assar (University Hospital RWTH Aachen, Aachen, Germany)

Discovery and validation of highly specific T-cell receptors for Immatics’s immunotherapeutic applications  
Speaker: Leonie Alten (Immatics Biotechnologies GmbH, Tuebingen, Germany)

Identification and profiling of PX-D26116, a potent Hydroxymidined-based IDO1 inhibitor  
Speaker: Simon Anderhub (Phenex Pharmaceuticals AG, Heidelberg, Germany)

Nur77, a new target to boost DC vaccination?  
Speaker: Marleen Ansems (Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands)

Zoledronic Acid suppresses tumour associated macrophages and myeloid derived suppressor cells in murine HCC  
Speaker: Misbah Aslam (University Medical Center of the Johannes Gutenberg-University, Mainz, Germany)

HPN424, a half-life extended, PSMA/CD3-specific TriTAC for the treatment of metastatic prostate cancer  
Speaker: Richard J. Austin (Harpoon Therapeutics, South San Francisco, United States)
Identification of exceptional therapeutic anti-CD40 agonists by optimal exploitation of rabbit antibody diversity through single B-cell cloning
Speaker: Karsten Beckmann (MAB Discovery GmbH, Neuried, Germany)

Identification of a naturally presented myeloma-associated BCMA peptide as an immunogenic T-cell epitope for immunotherapeutic approaches
Speaker: Tatjana Bilich (University of Tübingen, Institute for Cell Biology, Tübingen, Germany)

Citrullination: a mechanism to rapidly alert the immune system to cellular stress
Speaker: Victoria Brentville (Scancell Ltd, Nottingham, United Kingdom)

Citrullinated peptides from self-antigens can be presented by HLA-DP4 and can be targeted for tumor therapy
Speaker: Victoria Brentville (Scancell Ltd, Nottingham, United Kingdom)

CD8+ T cell immunity against phosphopeptide neoantigens and its potential use for monitoring checkpoint inhibitor therapy
Speaker: Nico Buettner (Medical Center University of Freiburg, Faculty of Medicine, Freiburg, Germany)

Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients
Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)

Selective FcγR engagement by CTLA-4 antibodies results in increased functional activity
Speaker: John Castle (Agenus Inc, Lexington, United States)

Mass spectrometry-based antigen discovery expands the cancer immunopeptidome
Speaker: Chloe Chong (Ludwig Center for Cancer Research, Epalinges, Switzerland)

Survivin, WT1 and SSX2: new targets for the immunotherapy of adult B-acute lymphoblastic leukaemia
Speaker: Leah Cooksey (The University of Hull, Hull, United Kingdom)

Cell-intrinsic and spatially distant tumor PD-L1 alters local and global anti-tumor immunity and responses to anti-PD-L1 or anti-PD-1 through novel chemokine and TIL effects
Speaker: Tyler Curiel (UT Health San Antonio, San Antonio, United States)

A novel aryl hydrocarbon receptor antagonist (PX-A24590) with anti-tumor activity in a syngeneic mouse pancreatic cancer model
Speaker: Ulrich Deuschle (Phenex Pharmaceuticals AG, Heidelberg, Germany)

Comprehensive characterization of IL-15-based tumor targeted Immunocytokines
Speaker: Laura Dix (Glycotope GmbH, Berlin, Germany)

Engineering novel antibody-based therapeutics for targeting of tumor endothelial marker 1 (TEM1)
Speaker: Julie Katrin Fierle (Ludwig Institute for Cancer Research at the University of Lausanne, Epalinges, Switzerland)

RIG-I agonist acts synergistically with PD1-checkpoint blockade as combinatorial immunotherapy in a model of hepatocellular carcinoma
Speaker: Simone Formisano (Klinikum der Universität München, Munich, Germany)

The immunopeptidomic landscape of primary versus recurrent disease in glioblastoma
Speaker: Lena Katharina Freudenmann (University of Tübingen, Interfaculty Institute for Cell Biology, Tübingen, Germany)

Tumor antigen-dependent T cell activation and tumor localization induced by a novel 4-1BB x 5T4 ADAPTIR™ bispecific antibody
Speaker: Sara Fritzell (Alligator Bioscience AB, Lund, Sweden)

Decoding the HLA immunopeptidome: Elucidating patterns of HLA allotype association and malignant cells
Speaker: Michael Ghosh (University of Tübingen, Tübingen, Germany)

Targeting the signal peptide in MMTV-associated breast cancer
Speaker: Jacob Hochman (The Hebrew University of Jerusalem, Jerusalem, Israel)
Development of an optimized scaffold for bispecific T cell receptor therapeutics
Speaker: Martin Hofmann (Immatics biotechnologies GmbH, Tuebingen, Germany)

Rapamycin and Zoledronic Acid strongly inhibit growth of advanced murine hepatocellular carcinoma via activation of innate and adaptive immunity
Speaker: Muhammad Ashfaq Khan (University Medical Center of the Johannes Gutenberg-University, Mainz, Germany)

Cytomegalovirus stimulates angiogenesis and emerges as a druggable target in glioblastoma
Speaker: Harald Krenzlin (Gutenberg-Universität Mainz, Mainz, Germany)

Immunopeptidomic profiling of triple negative breast cancer identifies potential immunotherapy target antigens
Speaker: Demin Li (University of Oxford, Oxford, United Kingdom)

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Speaker: Anne Månsson Kvarnhammar (Alligator Bioscience, Lund, Sweden)

Anticancer immunity mediated by the novel hexavalent human GITR agonist HERA-GITRL is conveyed by activating T cells without affecting Treg cells
Speaker: Viola Marschall (Apogenix AG, Heidelberg, Germany)

KY1055: a novel ICOS/PD-L1 bispecific antibody, enhances T cell activation and delivers potent monotherapy anti-tumor responses in vivo
Speaker: Matthew McCourt (Kymab, Cambridge, United Kingdom)

Detection of novel citrullinated targets for cancer therapy
Speaker: Rachael Metheringham (Scancell Limited, Nottingham, United Kingdom)

Identification of receptor binding partners via APEX2 proximity labeling
Speaker: Bastian Meyer (Klinikum der Universität München, Medizinische Klinik und Poliklinik II, München, Germany)

Identification and characterization of HLA-Ligands for immunotherapeutic approaches in oropharyngeal squamous-cell carcinoma
Speaker: Lena Mühlenbruch (University of Tübingen, Tübingen, Germany)

T cells against the N345K mutation of PIK3CA
Speaker: Julia Neufeld (Johannes Gutenberg University Medical Center, Mainz, Germany)

Human IL-10 (AM0010, Pegilodecakin) in combination with immune checkpoint blockade
Speaker: Martin Oft (ARMO BioSciences, Redwood City, United States)

Establishment of a human CD3ε transgenic mouse model to assess anti-tumor efficacy of human T-cell-redirecting bispecific antibodies
Speaker: Davy Xuesong Ouyang (Crown Bioscience Inc., Santa Clara, United States)

DSP106 - a novel PD1-CD70 dual signaling protein (DSP) for cancer immunotherapy
Speaker: Yehudith Jitka Sagiv (Kahr Medical Ltd, Jerusalem, Israel)

Human endogenous retroviruses as a potential reservoir for T cell mediated cancer immunotherapy
Speaker: Sunil Kumar Saini (Technical University of Denmark, Lyngby, Denmark)

Depletion of intratumoural regulatory T cells by the anti-ICOS antibody KY1044 in combination with immune checkpoint blockade enhances the anti-tumour response in pre-clinical models.
Speaker: Richard Sainson (Kymab, Cambridge, United Kingdom)

Glyco-engineering of an anti-CD40 antibody enhances its agonistic activity
Speaker: Phillip Schiele (Glycotope GmbH, Berlin, Germany)

Database matching of de novo sequencing candidates - a new strategy for MHC peptide identification
Speaker: Andreas Schlosser (Universität Würzburg, Würzburg, Germany)
HERA-LIGHT, a novel hexavalent HVEM agonist promoting T cell activation and expansion  
Speaker: Julian P. Sefrin (Apogenix AG, Heidelberg, Germany)

Theranostic tumor imaging of neuroblastoma using radiolabeled αCD276-antibody  
Speaker: Dominik Sonanini (Eberhard Karls University of Tübingen, Tübingen, Germany)

Expression data integration: advancing immuno-oncology target discovery  
Speaker: Frank Staubli (NEBION AG, Zurich, Switzerland)

Setup and validation of a T cell receptor maturation platform resulting in high-affinity binders for engineering of bispecific molecules  
Speaker: Felix Unverdorben (Immatics biotechnologies GmbH, Tuebingen, Germany)

Tumour glycan-targeting monoclonal antibodies - Candidate immunogenic cell death inducers  
Speaker: Mireille Vankemmelbeke (Scancell Ltd, Nottingham, United Kingdom)

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell non-Hodgkin lymphoma  
Speaker: Sébastien Wächli (Oslo University Hospital, Oslo, Norway)

Cloning, expression and functional characterization of an HLA-C*07:01-restricted αβ T-cell receptor against chondroitin sulfate proteoglycan 4 (CSPG4)  
Speaker: Catherine Wölfel (Internal Medicine III, Mainz, Germany)

GARP expressing platelets and the induction of peripheral tolerance: A novel target for anti-tumor-therapy?  
Speaker: Niklas Zimmer (University Medical Center Mainz, Mainz, Germany)

**Meet the Editor**

**An editors guide to scientific publishing**  
Speaker: Priscilla Kelly (Science Magazine, Washington, DC, United States)

**CIMT Members Meeting**

17:30 - 19:00  
Dijon Room

**General Members Assembly of the Association for Cancer Immunotherapy CIMT**

19:30 - 24:00  
Foyer

**Social Event & Poster Award Ceremony**
Plenary Session
08:30 - 10:00
Congress Hall

Immunoguiding
Chair: Marij J.P. Welters (Leiden University Medical Center, Leiden, Netherlands)
Chair: Sine Reker Hadrup (Technical University of Denmark, Copenhagen, Denmark)

Reprogramming the tumor microenvironment for efficient cancer immunotherapy
Speaker: Günter J. Hämerling (German Cancer Research Center DKFZ, Heidelberg, Germany)
08:30 - 09:00

Complement in cancer: untangling an intricate relationship
Speaker: Dimitrios Mastellos (National Center for Scientific Research 'Demokritos', Athens, Greece)
09:00 - 09:30

Lung cancer evolution and immune escape
Speaker: Nicholas McGranahan (Cancer Research UK Lung Cancer Centre of Excellence, London, United Kingdom)
09:30 - 10:00

Break
10:00 - 10:30
Foyer

Coffee Break

Plenary Session
10:30 - 12:30
Congress Hall

Regulatory Research organized by CIMT-RRG and CARAT
Chair: Ulrich Kalinke (TWINCORE, Hanover, Germany)
Chair: Christian Buchholz (Paul-Ehrlich-Institut, Langen, Germany)

Chimeric antigen receptor (CAR) modified T cells - EU regulatory considerations
Speaker: Martina Schüssler-Lenz (Committee for Advanced Therapies (CAT), European Medicines Agency, London, United Kingdom)
10:30 - 11:10

From Karl Landsteiner to CAR-T cells: from processes to products and patients
Speaker: Martin Hildebrandt (Technical University Munich, Munich, Germany)
11:10 - 11:50

Translation of CAR-based innovations into clinics: how to overcome the regulatory hurdles
Speaker: Bernd Schröder (Miltenyi Biotech, Teterow, Germany)
11:50 - 12:30

Short Talk Session
10:30 - 11:45
Gutenberg Hall A

Short Talk Session IV Therapeutic Vaccination
Chair: Sebastian Kreiter (TRON, Mainz, Germany)
Chair: Kris Thielemans (Vrije Universiteit Brussel, Brussels, Belgium)
Bifunctional RNA-nanoparticles to enhance dendritic cell activation and enable MRI-based detection of dendritic cell migration to lymph nodes
Speaker: Adam Grippin (University of Florida Brain Tumor Immunotherapy Program, Gainesville, United States)

Enrichment of gene modified cellular melanoma vaccines with melanoma stem cells or inducible pluripotent stem cells increases immunogenicity and clinical effectiveness in mice
Speaker: Andrzej Mackiewicz (Poznań University of Medical Sciences, Poznań, Poland)

Local radiotherapy and E7-RNA-LPX vaccination activate non-redundant mechanisms and lead to complete tumor rejection of well-established HPV16+ TC-1 tumors
Speaker: Nadja Salomon (TRON, Mainz, Germany)

NKG2A blockade potentiates CD8+ T-cell immunity induced by cancer vaccines
Speaker: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)

Biomaterial-based scaffolds improve delivery of therapeutic nanoparticle cancer vaccines to dendritic cells
Speaker: Jorieke Weiden (Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands)

Short Talk Session
10:30 - 11:45
Gutenberg Hall B

Short Talk Session V Immunomonitoring
Chair: Cecile Gouttefangeas (University of Tübingen, Tübingen, Germany)
Chair: Dimitrios Mastellos (National Center for Scientific Research ‘Demokritos’, Athens, Greece)

High dimensional analysis of the myeloid cell landscape in human breast cancer metastatic lymph nodes
Speaker: Rodrigo Nalio Ramos (Institute Curie, Paris, France)

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival
Speaker: Saskia J.A.M. Santegoets (Leiden University Medical Center, Leiden, Netherlands)

Empty MHC class I molecules: An alternate, convenient, and improved detection tool for antigen specific T cells
Speaker: Tripti Tamhane (Technical University of Denmark, Lyngby, Denmark)

Immunomonitoring for personalized cancer immunotherapies via ex vivo combinatorial workflow and concurrent high-resolution class I & II ICS
Speaker: Alexander Ulges (Immatics Biotechnologies GmbH, Tübingen, Germany)

Disappearance of NY-ESO-1 and Melan-A-specific T-cells from peripheral blood is associated with clinical response in melanoma patients undergoing anti-PD-1 therapy
Speaker: Henning Zelba (University Medical Center Tübingen, Tübingen, Germany)

Short Talk Session
11:45 - 13:00
Gutenberg Hall A

Short Talk Session VI Improving Immunity
Chair: Mustafa Diken (TRON, Mainz, Germany)
Chair: Onur Boyman (University Hospital Zurich, Zurich, Switzerland)
Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable treatment of solid tumors with T cell therapies
Speaker: Riikka Havunen (University of Helsinki, Helsinki, Finland)

Intratumoral RNA treatment: a promising approach for the therapy of solid tumors
Speaker: Katja Fiedler (CureVac AG, Tübingen, Germany)

Human interleukin-2 (IL-2)/anti-IL-2 antibody complexes preferentially stimulate effector cells and show strong efficacy in tumor models
Speaker: Andreas Katopodis (Novartis Institutes of Biomedical Research, Basel, Switzerland)

Activin-A protects against lung cancer progression by potentiating anti-tumor immunity
Speaker: Ioannis Morianos (Biomedical Research Foundation of the Academy of Athens, Athens, Greece)

Loss of myeloid cell GCN2 drives progression in experimental melanomas during immune checkpoint inhibition
Speaker: Jana K. Sonner (German Cancer Research Center DKFZ, Heidelberg, Germany)

Short Talk Session
11:45 - 13:00

Short Talk Session VII Clinical Trials
Chair: Anthony Kong (University of Birmingham, Birmingham, United Kingdom)
Chair: Stephan Grabbe (University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany)

HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients
Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)

CetuGEX and Cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) - p16+ subgroup analysis of the phase 2 RESGEX study
Speaker: Beate Habel (Glycotope GmbH, Berlin, Germany)

The safety, tolerability, and preliminary clinical activity of the CXCR4 inhibitor X4P-001 and nivolumab in renal cell carcinoma patients that are refractory to nivolumab monotherapy
Speaker: Tracy L. Rose (Lineberger Comprehensive Cancer Center, Chapel Hill, United States)

High rate of objective anti-tumor response in 9 patients with primary or recurrent glioblastoma after viro-immunotherapy with oncolytic parvovirus H-1 in combination with bevacumab and PD-1 checkpoint blockade
Speaker: Karsten Geletneky (Klinikum Darmstadt, Darmstadt, Germany)

Human IL-10 (AM0010, Pegilodecakin) in combination with immune checkpoint blockade
Speaker: Martin Oft (ARMO BioSciences, Redwood City, United States)
## Therapeutic Vaccination

Chair: Hans-Georg Rammensee (University of Tübingen, Tübingen, Germany)  
Chair: Carl Figdor (Radboud University Medical Center, Nijmegen, Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:30</td>
<td><strong>Dendritic cell-based vaccination against cancer</strong></td>
<td>Jolanda de Vries (Radboud University Medical Center, Nijmegen, Netherlands)</td>
<td>Radboud University Medical Center, Nijmegen, Netherlands</td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td><strong>Personalized RNA vaccines</strong></td>
<td>Özlem Türeci (German Cluster of Individualized Immunointervention (CI3), Mainz, Germany)</td>
<td>German Cluster of Individualized Immunointervention (CI3), Mainz, Germany</td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td><strong>Therapeutic cancer vaccine for combination with immune checkpoint blockade therapy: formulation matters</strong></td>
<td>Yared Hailemichael (MD Anderson Cancer Center, Houston, United States)</td>
<td>MD Anderson Cancer Center, Houston, United States</td>
</tr>
</tbody>
</table>